What is Nudge?
Non-invasive whole-brain interface company using focused ultrasound.
- Category
- Neurotechnology
- Headquarters
- San Francisco, CA
- Founded
- 2024
- Employees
- 11-50 reported
- Total funding
- $100M disclosed
- Status
- Private; Series A
What is Nudge?
Nudge is a neurotechnology company. Nudge says it is building whole-brain interfaces for everyday life and running studies of non-invasive focused-ultrasound technology.
Nudge is a neurotechnology company with headquarters listed as San Francisco, CA. Non-invasive whole-brain interface company using focused ultrasound. Nudge says it is building whole-brain interfaces for everyday life and running studies of non-invasive focused-ultrasound technology.
The company is currently best read as Private; Series A. Public sources show $100M disclosed in funding and Not publicly disclosed; where revenue, ARR, margin, or exact customer counts are not published, this profile avoids inventing them and uses funding, footprint, product coverage, and public scale signals instead.
For sellers, the account matters because buying centers span clinical operations, compliance, product, data, security, finance, and growth. The strongest pitch is tied to measurable access, quality, cost, workflow, or workforce outcomes rather than generic software adoption.
Sources:Nudge homepageNudge Series A
What does Nudge offer?
Nudge offers Focused ultrasound neuromodulation, Nudge Zero research device, Brain measurement, Brain modulation, and related workflows.
- Focused ultrasound neuromodulation· Core product
- Nudge Zero research device· Core product
- Brain measurement· Care workflow
- Brain modulation· Care workflow
- Clinical studies· Expansion
- Future consumer neurotechnology· Expansion
Sources:Nudge homepageNudge Series A
How does Nudge make money?
Nudge is pre-commercial or early research-stage; future revenue likely depends on regulated clinical indications, research partnerships, and eventually consumer or prescribed device channels.
Nudge is pre-commercial or early research-stage; future revenue likely depends on regulated clinical indications, research partnerships, and eventually consumer or prescribed device channels.
No commercial pricing is published. Current public calls to action are study participation and recruiting, not a paid product catalog. Growth is driven by adoption in neurotechnology, expansion into larger accounts or additional geographies, and proof that the product improves outcomes, cost, capacity, or experience.
Because the company is private, this profile does not invent revenue, gross margin, or unit economics. Sellers should qualify budget owner, reimbursement model, procurement path, compliance requirements, and integration effort early.
Sources:Nudge homepageNudge Series A
Who leads Nudge?
Nudge is led by Fred Ehrsam, Quintin Frerichs, Jeremy Barenholtz.
- Fred EhrsamCo-founder & CEOFounderCoinbase and Paradigm co-founder now leading Nudge.
- Quintin FrerichsCo-founderFounderCo-founded Nudge and writes publicly about human-enhancement companies.
- Jeremy BarenholtzCo-founder, President & CTOFounding teamFormer Neuralink engineer working on focused-ultrasound neuromodulation.
How do you contact Nudge's leadership?
Nudge does not publish verified personal executive emails in the reviewed public sources. Use official company contact, demo, support, partnerships, or careers routes rather than guessed personal emails.
Personal executive email format not verified; use official company routingSources:Nudge homepageNudge Series A
How much funding has Nudge raised?
Nudge has $100M disclosed in public or reported funding; latest disclosed round: Jul 2025 Series A ($100M).
Nudge's disclosed funding history is: Jul 2025 Series A: $100M, valuation not disclosed, led/backed by Thrive Capital and Greenoaks.
The latest public valuation/status used here is Not publicly disclosed. If a valuation is not disclosed, this profile treats the company as private with no public priced mark rather than inferring a number from round size.
Seller signal: funding indicates capacity to invest, but healthcare buyers still require security, compliance, implementation proof, and outcomes evidence. New capital is most likely to support market expansion, hiring, product development, clinical operations, data, AI, and partnerships.
How did Nudge get here?
Nudge reached its current stage through founding, product expansion, and major financing milestones.
- 2024FoundedFred Ehrsam and Quintin Frerichs co-found Nudge.
- Apr 2025Mission publishedNudge describes its technology and study approach.
- Jul 2025$100M Series ANudge announces major financing led by Thrive and Greenoaks.
- 2025Research studiesNudge describes current studies and non-invasive ultrasound approach.
- 2026Hiring and research scaleNudge continues building scientific and engineering teams in San Francisco.
Sources:Nudge homepageNudge Series A
Who are Nudge's competitors?
Nudge competes with adjacent healthcare providers, software platforms, marketplaces, and care-navigation companies.
- NeuralinkImplantable brain-computer interface company.
- SynchronEndovascular brain-computer interface developer.
- Precision NeuroscienceMinimally invasive brain-computer interface platform.
- ParadromicsHigh-data-rate implantable BCI company.
- NeurableNon-invasive neurotechnology for attention and brain-signal products.
Sources:Nudge homepageNudge Series A
Nudge — frequently asked questions
